HISTAPHARMBI-ENZYMATIC GI INNOVATION
MENU ☰
NOW RECEIVING STRATEGIC PARTNERSHIP OFFERS

14 WAYS
TO SAY YES.

Two platforms. One bi-enzymatic vision.
The deal structure?

Histapharm is now welcoming serious proposals for investment, licensing, co-development, commercialization and acquisition. We've mapped 14 ways to work together. You have the 15th idea? Propose the ring, we might agree!

PROPOSE A PARTNERSHIP EXPLORE THE OPTIONS
A different perspective on GI health. No one-size-fits-all term sheet.
YOUR OPTIONS 14 WAYS IN
FOUR PARTNERSHIP FAMILIES
14 ways in.
4 easy starting points. 4 investment + 4 licensing + 3 co-development + 3 acquisition.
THE SCIENCE BEHIND THE OPPORTUNITY

GI challenges are complex.
Our thinking has two tracks.

Histapharm is exploring a new bi-enzymatic perspective on gastrointestinal conditions through two distinct development platforms. Different development paths. A shared scientific vision. And room for the right partners to help shape what comes next.

PLATFORM A / NUTRACEUTICAL · PHARMA PATH

EquiHista®

Bi-enzymatic · Oral · Tablet

A patented bi-enzymatic oral tablet for gastrointestinal applications.

PLATFORM B / MEDICAL DEVICE · PHARMA PATH

InWorks®

Bi-enzymatic · Novel · Candidate

An undisclosed bi-enzymatic novel candidate for undisclosed medical GI conditions.

One scientific vision. Two platforms. Fourteen potential partnership structures. The gut is complicated. Partnering with us doesn't have to be. ↗
THE OPPORTUNITY / BUILT TO FIT

Four strategic umbrellas.
Fourteen practical ways in.

We've organized 14 potential deal structures into four partnership families: 4 investment routes, 4 licensing and commercialization routes, 3 co-development routes, and 3 acquisition or special-situation routes. The right agreement is built together.

14 PARTNERSHIP WAYS4 + 4 + 3 + 3 = 14
01 / INVEST

Strategic
Investment

Equity participation, strategic capital and creative investment structures.

4 STRUCTURES 02 / SCALE

Licensing &
Commercialization

Licensing, territorial rights, distribution and commercialization alliances.

4 STRUCTURES 03 / BUILD

Co-development &
Joint Ventures

Joint R&D, development alliances and strategic scientific collaboration.

3 STRUCTURES 04 / ACQUIRE

Acquisition &
Special Situations

Strategic combinations, asset transactions and full acquisition proposals.

3 STRUCTURES
14 potential structures, grouped into 4 families. These cards are categories, not the complete list of deal structures. Every proposal is considered on its merits.YOUR STRATEGY + OUR SCIENCE = A CONVERSATION WORTH HAVING ↗
OUR APPROACH

Serious science.
Open minds.

We bring a biotechnology approach spanning two development platforms and an intellectual-property foundation. You bring the vision, expertise or resources that can help move it forward. The right structure follows the right strategic fit.

Initial discussions use non-confidential information. Detailed material is shared through an appropriate confidentiality process.

“

We've identified fourteen ways to make a deal. We're much more interested in finding your reason to make one.

HISTAPHARM · PARTNERSHIPS
LET'S MAKE SOMETHING HAPPEN

YOUR MOVE

Think we could build something meaningful together? Send us your idea. We promise not to reply with a generic 47-slide deck.

START THE CONVERSATION

Mike Baron
VP, Business Development & Co-Founder
mikeb@histapharm.com

© 2026 Histapharm Inc. | Longueuil, Quebec, Canada. Partnerships are subject to mutual evaluation and definitive agreements. The two platforms are development-stage initiatives; no safety, efficacy, regulatory-approval or commercial-availability claims are implied. No unpublished intellectual property, confidential results, financial terms or proprietary know-how are disclosed on this page. Corporate website ↗